Table 2 Demographic and clinicopathological data for stage II EC patients per the 2023 FIGO staging system
Variables | Total | IIA | IIB | IIC | p-value |
|---|---|---|---|---|---|
n = 80 (%) | n = 26 (%) | n = 18 (%) | n = 36 (%) | ||
Age (years) | Â | Â | Â | Â | 0.110 |
 < 65 | 66 (82.50) | 24 (92.31) | 16 (88.89) | 26 (72.22) |  |
 ≥ 65 | 14 (17.50) | 2 (7.69) | 2 (11.11) | 10 (27.78) |  |
Surgical approach | Â | Â | Â | Â | 0.032 |
 Laparoscope | 62 (77.50) | 19 (73.08) | 18 (100.00) | 25 (69.44) |  |
 Laparotomy | 18 (22.50) | 7 (26.92) | 0 (0.00) | 11 (30.56) |  |
Surgical scope | Â | Â | Â | Â | 0.088 |
 RH/mRH | 52 (65.00) | 21 (80.77) | 9 (50.00) | 22 (61.11) |  |
 SH | 28 (35.00) | 5 (19.23) | 9 (50.00) | 14 (38.89) |  |
Flushing fluid cytology | Â | Â | Â | Â | 0.234 |
 Negative | 67 (83.75) | 22 (84.62) | 13 (72.22) | 32 (88.89) |  |
 Positive | 4 (5.00) | 0 (0.00) | 2 (11.11) | 2 (5.56) |  |
 Deficiency | 9 (11.25) | 4 (15.38) | 3 (16.67) | 2 (5.56) |  |
Pathological type |  |  |  |  | < 0.001 |
 Non-aggressive | 44 (55.00) | 26 (100.00) | 18 (100.00) | 0 (0.00) |  |
 Aggressive | 36 (45.00) | 0 (0.00) | 0 (0.00) | 36 (100.00) |  |
Histological grade |  |  |  |  | < 0.001 |
 G1 | 27 (33.75) | 17 (65.38) | 9 (50.00) | 1 (2.78) |  |
 G2 | 19 (23.75) | 9 (34.62) | 9 (50.00) | 1 (2.78) |  |
 G3 | 34 (42.50) | 0 (0.00) | 0 (0.00) | 34 (94.44) |  |
Tumor diameter (cm) | Â | Â | Â | Â | 0.505 |
 <5 | 58 (72.50) | 18 (69.23) | 15 (83.33) | 25 (69.44) |  |
 ≥5 | 22 (27.50) | 8 (30.77) | 3 (16.67) | 11 (30.56) |  |
Invasion of the myometrium | Â | Â | Â | Â | 0.089 |
 < 1/2 | 50 (62.50) | 20 (76.92) | 8 (44.44) | 22 (61.11) |  |
 ≥1/2 | 30 (37.50) | 6 (23.08) | 10 (55.56) | 14 (38.89) |  |
Invasion of cervical stroma |  |  |  |  | < 0.001 |
 No | 46 (57.50) | 0 (0.00) | 17 (94.44) | 29 (80.56) |  |
 Yes | 34 (42.50) | 26 (100.00) | 1 (5.56) | 7 (19.44) |  |
LVSI |  |  |  |  | < 0.001 |
 No | 34 (42.50) | 18 (69.23) | 0 (0.00) | 16 (44.44) |  |
 Focal | 23 (28.75) | 8 (30.77) | 0 (0.00) | 15 (41.67) |  |
 Universality | 23 (28.75) | 0 (0.00) | 18 (100.00) | 5 (13.89) |  |
P53 |  |  |  |  | < 0.001 |
 Wild type | 67 (83.75) | 25 (96.15) | 18 (100.00) | 24 (66.67) |  |
 Mutant type | 13 (16.25) | 1 (3.85) | 0 (0.00) | 12 (33.33) |  |
Ki67 index (%) | Â | Â | Â | Â | 0.002 |
 <70 | 36 (45.00) | 19 (73.08) | 6 (33.33) | 11 (30.56) |  |
 ≥70 | 44 (55.00) | 7 (26.92) | 12 (66.67) | 25 (69.44) |  |
Adjuvant chemotherapy | Â | Â | Â | Â | 0.149 |
 No | 28 (35.00) | 13 (50.00) | 5 (27.78) | 10 (27.78) |  |
 Yes | 52 (65.00) | 13 (50.00) | 13 (72.22) | 26 (72.22) |  |
Adjuvant radiotherapy | Â | Â | Â | Â | 0.884 |
 No | 54 (67.50) | 17 (65.38) | 13 (72.22) | 24 (66.67) |  |
 Yes | 26 (32.50) | 9 (34.62) | 5 (27.78) | 12 (33.33) |  |